- Home
- ACTU
as 11-22-2024 4:00pm EST
Stocks
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 153.1M | IPO Year: | 2024 |
| Target Price: | N/A | AVG Volume (30 days): | 59.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.51 - $10.16 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ACTUATE THERAPEUTICS INC News
ACTU Breaking Stock News: Dive into ACTU Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
GlobeNewswire
25 days ago
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development
GlobeNewswire
2 months ago
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor
GlobeNewswire
2 months ago
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
GlobeNewswire
2 months ago
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
GlobeNewswire
2 months ago
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
GlobeNewswire
3 months ago
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
3 months ago
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
Compare ACTU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACTU ACTUATE THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.